FPR2 agonists such as ANXA1 (Tourki, Kain, Pullen, et al., 2020), Ac‐ANXA1 (2‐26) (Qin et al., 2019), RvD1 (Kain et al., 2015), BMS‐986235 (Asahina et al., 2020; Garcia et al., 2021) and LXA4 (Kain et al., 2017) are cardioprotective in experimental models of myocardial infarction. Here, ANXA1 is linked to myocardial infarction.